Please login to the form below

Not currently logged in
Email:
Password:

NKT-214

This page shows the latest NKT-214 news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

BMS presses go on Nektar combo pivotal trials, despite data debate

Specifically, Opdivo and NKTR-214 achieved an overall response rate (ORR) of 85% in stage 1 - i.e. ... In fact, they have data which suggests NKTR-214 can actually make PD-L1-negative tumours start expressing the biomarker.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...